Cervesi Chiara, Park Su Young, Galling Britta, Molteni Silvia, Masi Gabriele, Gerhard Tobias, Olfson Mark, Correll Christoph U
Institute for Maternal and Child Health, IRCCS "Burlo Garofolo," Trieste, Italy.
Department of Pediatrics, University of Padua, Italy.
J Clin Psychiatry. 2017 Mar;78(3):347-357. doi: 10.4088/JCP.15r10435.
To meta-analytically examine the trends and correlates of antipsychotic use in youth with mood disorders.
Systematic literature search without language restriction in PubMed/MEDLINE/PsycINFO from database inception through March 2015 using the following search terms: (antipsychotic* OR neuroleptic* OR "dopamine blocker*" OR antidopaminergic) AND (child* OR adolescen* OR pediatric OR youth) AND (prescription* OR prescrib* OR use OR utilization OR database OR pharmacoepidemiolog* OR frequency OR rate OR rates). Random effects meta-analysis and meta-regression analyses were conducted.
Included were studies reporting on the frequency of (1) mood disorders in antipsychotic-treated youth (≤ 19 years) and (2) antipsychotic use in youth with mood disorders.
Two independent investigators abstracted data on study, patient, and treatment characteristics.
Forty-one studies were meta-analyzed (N = 518,919, mean ± SD age = 12.8 ± 1.8 years, males = 65.7%). Altogether, 24.2% of antipsychotic-treated youth had a mood disorder diagnosis (studies = 34, depression spectrum disorder = 10.9%, bipolar spectrum disorder = 13.6%). In longitudinal studies, the overall proportion increased significantly from 17.3% in 2000 (range, 1996-2009) to 24.5% in 2006 (range, 2004-2011) (odds ratio [OR] = 1.50; 95% confidence interval [CI], 1.26-1.79; P < .0001). This increase was driven entirely by bipolar spectrum diagnoses (2001 = 11.1%, 2006 = 16.3%, P < .0001), rather than depression spectrum diagnoses (2001 = 9.1%, 2007 = 9.2%, P = .77). Among youth with mood disorders (8 studies), 24.0% received antipsychotics (depression spectrum disorder = 4.6%; bipolar spectrum disorder = 44.0%).
The proportion of youth with mood disorder diagnoses increased significantly among antipsychotic-treated youth, driven entirely by an increase in youth with bipolar spectrum disorders. Progress in understanding the reasons for these trends and for an evaluation of the appropriateness of the observed antipsychotic prescribing requires more detailed information than is available in traditional pharmacoepidemiologic databases.
通过荟萃分析研究患有情绪障碍的青少年使用抗精神病药物的趋势及相关因素。
在PubMed/MEDLINE/PsycINFO数据库中进行系统文献检索,检索时间从建库起至2015年3月,检索词如下:(抗精神病药或神经阻滞剂或“多巴胺阻滞剂*”或抗多巴胺能药)与(儿童或青少年或儿科或青年)与(处方或开处方或使用或利用或数据库或药物流行病学*或频率或率或比率)。进行随机效应荟萃分析和荟萃回归分析。
纳入的研究报告了以下方面的频率:(1)接受抗精神病药物治疗的青少年(≤19岁)中的情绪障碍;(2)患有情绪障碍的青少年使用抗精神病药物的情况。
两名独立研究人员提取了关于研究、患者和治疗特征的数据。
对41项研究进行了荟萃分析(N = 518,919,平均±标准差年龄 = 12.8 ± 1.8岁,男性 = 65.7%)。总体而言,接受抗精神病药物治疗的青少年中有24.2%被诊断为患有情绪障碍(研究数量 = 34,抑郁谱系障碍 = 10.9%,双相谱系障碍 = 13.6%)。在纵向研究中,总体比例从2000年的17.3%(范围为1996 - 2009年)显著增加至2006年的24.5%(范围为2004 - 2011年)(优势比[OR] = 1.50;95%置信区间[CI],1.26 - 1.79;P <.0001)。这种增加完全由双相谱系诊断驱动(2001年 = 11.1%,2006年 = 16.3%,P <.0001),而非抑郁谱系诊断(2001年 = 9.1%,2007年 = 9.2%,P =.77)。在患有情绪障碍的青少年中(8项研究),24.0%使用了抗精神病药物(抑郁谱系障碍 = 4.6%;双相谱系障碍 = 44.0%)。
在接受抗精神病药物治疗的青少年中,被诊断为患有情绪障碍的青少年比例显著增加,这完全是由双相谱系障碍青少年数量的增加所驱动。要进一步了解这些趋势的原因以及评估所观察到的抗精神病药物处方的合理性,需要比传统药物流行病学数据库中更详细的信息。